Supplementary Table 2.
Basic Characteristics of Vaccinated Individuals With and Without IBD and Unvaccinated Individuals With and Without IBD in Unmatched Cohort
| Not vaccinated |
Vaccinated |
P value | SMD | |||||
|---|---|---|---|---|---|---|---|---|
| IBD (N = 4890) | Non-IBD (N = 23,356) | P value | SMD | IBD (N = 12,109) | Non-IBD (N = 31,427) | |||
| Age (y) | 52 ± 24 | 51 ± 23 | <.001 | 0.054 | 48 ± 18 | 48 ± 17 | .026 | 0.024 |
| Age group (y) | <.001 | 0.155 | <.001 | 0.066 | ||||
| <18 | 279 (5.7%) | 990 (4.2%) | 138 (1.1%) | 298 (0.9%) | ||||
| 18–39 | 1451 (30%) | 7553 (32%) | 4008 (33%) | 10,499 (33%) | ||||
| 40–49 | 838 (17%) | 3723 (16%) | 2262 (19%) | 6400 (20%) | ||||
| 50–59 | 626 (13%) | 3140 (13%) | 2165 (18%) | 5811 (19%) | ||||
| 60–69 | 426 (8.7%) | 2609 (11%) | 1737 (14%) | 4207 (13%) | ||||
| 70–79 | 430 (8.8%) | 2216 (9.5%) | 1263 (10%) | 3016 (10%) | ||||
| 80+ | 840 (17.2%) | 3125 (13%) | 536 (4.4%) | 1196 (3.8%) | ||||
| Sex, male | 2500 (51%) | 12,256 (53%) | .088 | 0.027 | 6030 (50%) | 15,372 (49%) | .1 | 0.018 |
| Disease duration (y) | 11 (5.7–17) | — | 12 (6.1–18) | — | ||||
| Weeks from second vaccine | — | — | 21 (18–23) | 20 (17–22) | <.001 | 0.21 | ||
| BMI category | <.001 | 0.409 | <.001 | 0.502 | ||||
| Overweight (25–29.9 kg/m2) | 174 (3.6%) | 253 (1.1%) | 734 (6.1%) | 736 (2.3%) | ||||
| Obese (30–39.99 kg/m2) | 196 (4.0%) | 538 (2.3%) | 930 (7.7%) | 2096 (6.7%) | ||||
| Severe obesity (>40 kg/m2) | 67 (1.4%) | 313 (1.3%) | 330 (2.7%) | 1184 (3.8%) | ||||
| Pregnancy | 117 (2.4%) | 438 (1.9%) | .02 | 0.036 | 199 (1.6%) | 623 (2.0%) | .022 | 0.025 |
| Treatment over last year | ||||||||
| Anti-TNF | 0 (0%) | 0 (0%) | 1 | <0.001 | 452 (3.7%) | 0 (0%) | <.001 | 0.519 |
| Corticosteroids | 167 (3.4%) | 0 (0%) | <.001 | 0.266 | 105 (0.9%) | 0 (0%) | <.001 | 0.278 |
| Immunomodulators | 187 (3.8%) | 0 (0%) | <.001 | 0.282 | 217 (1.8%) | 0 (0%) | <.001 | 0.336 |
| Mesalamine | 553 (11%) | 0 (0%) | <.001 | 0.505 | 738 (6.1%) | 0 (0%) | <.001 | 0.386 |
| Vedolizumab | 88 (1.8%) | 0 (0%) | <.001 | 0.191 | 122 (1.0%) | 0 (0%) | <.001 | 0.292 |
| Ustekinumab | 55 (1.1%) | 0 (0%) | <.001 | 0.151 | 76 (0.6%) | 0 (0%) | <.001 | 0.213 |
| Tofacitinib | 11 (0.2%) | 0 (0%) | <.001 | 0.067 | 9 (0.1%) | 0 (0%) | <.001 | 0.096 |
| IBD surgery ever | 736 (15%) | 0 (0%) | <.001 | 0.595 | 1689 (14%) | 0 (0%) | <.001 | 0.569 |
| IBD hospitalization ever | 2668 (55%) | 0 (0%) | <.001 | 1.55 | 5909 (49%) | 0 (0%) | <.001 | 1.381 |
| Corticosteroids use ever | 2705 (55%) | 0 (0%) | <.001 | 1.574 | 6922 (57%) | 0 (0%) | <.001 | 1.634 |
| Preexisting conditions scorea | <.001 | 0.461 | <.001 | 0.145 | ||||
| 0 | 2053 (42%) | 14988 (64%) | 4922 (41%) | 14,761 (47%) | ||||
| 1 | 1142 (23%) | 3584 (15%) | 3412 (28%) | 8545 (27%) | ||||
| 2 | 571 (12%) | 1712 (7.3%) | 1664 (14%) | 3756 (12%) | ||||
| 3 | 367 (7.5%) | 1180 (5.1%) | 935 (7.7%) | 2109 (6.7%) | ||||
| 4+ | 757 (16%) | 1892 (8.1%) | 1176 (10%) | 2256 (7.2%) | ||||
| Preexisting conditions | ||||||||
| Cancer | 250 (5.1%) | 766 (3.3%) | <.001 | 0.092 | 582 (4.8%) | 1201 (3.8%) | <.001 | 0.048 |
| Chronic kidney disease | 399 (8.2%) | 942 (4%) | <.001 | 0.173 | 578 (4.8%) | 922 (2.9%) | <.001 | 0.096 |
| Chronic obstructive pulmonary disease | 382 (7.8%) | 854 (3.7%) | <.001 | 0.179 | 548 (4.5%) | 1123 (3.6%) | <.001 | 0.048 |
| Heart conditions | 857 (18%) | 2373 (10%) | <.001 | 0.214 | 1314 (11%) | 2728 (8.7%) | <.001 | 0.073 |
| Organ transplant | 13 (0.3%) | 24 (0.1%) | .008 | 0.038 | 29 (0.2%) | 34 (0.1%) | .002 | 0.032 |
| Sickle cell | 0 (0%) | 0 (0%) | 1 | <0.001 | 0 (0%) | 0 (0%) | 1 | <0.001 |
| Type II diabetes | 705 (14%) | 2461 (11%) | <.001 | 0.118 | 1641 (14%) | 3954 (13%) | .007 | 0.029 |
| Asthma | 1038 (21%) | 2385 (10%) | <.001 | 0.306 | 2717 (22%) | 5474 (17%) | <.001 | 0.126 |
| Cerebrovascular disease | 527 (11%) | 1446 (6.2%) | <.001 | 0.165 | 927 (7.7%) | 1932 (6.1%) | <.001 | 0.06 |
| Other respiratory disease | 106 (2.2%) | 126 (0.5%) | <.001 | 0.141 | 186 (1.5%) | 279 (0.9%) | <.001 | 0.059 |
| Hypertension | 1427 (29%) | 4573 (20%) | <.001 | 0.225 | 3234 (27%) | 8315 (27%) | .606 | 0.006 |
| Immunocompromised state | 19 (0.4%) | 59 (0.3%) | .134 | 0.024 | 40 (0.3%) | 73 (0.2%) | .09 | 0.019 |
| Type I diabetes | 115 (2.4%) | 371 (1.6%) | <.001 | 0.055 | 252 (2.1%) | 540 (1.7%) | .012 | 0.027 |
| Liver disease | 513 (11%) | 1188 (5.1%) | <.001 | 0.203 | 1634 (14%) | 3309 (11%) | <.001 | 0.091 |
| Thalassemia | 48 (1.0%) | 96 (0.4%) | <.001 | 0.069 | 108 (0.9%) | 247 (0.8%) | .297 | 0.012 |
NOTE. Count (%), mean ± standard deviation, or medians (IQR) are presented as appropriate.
BMI, body mass index.
a
Number of preexisting conditions defined by the Centers for Disease Control as risk factors (Appendix 1).